Shineco

Shineco, Inc. is a holding company, which through its subsidiaries, engages in the production and distribution of plant-based products. It operates through the following segments: Luobuma Products, Herbal Products, and Other Agricultural Products. The Luobuma Products segment focuses in the development, manufacture, and distribution of specialized fabrics, textile products, and other by-products derived from an indigenous Chinese plant called Apocynum Venetum. The Herbal Products segment involves in the processing and distribution of traditional Chinese medicinal herbal products as well as other pharmaceutical products. The Other Agricultural Products segment comprises planting, processing, and distribution of green and organic agricultural produce and growing and cultivating of Chinese Yew trees. The company was founded on August 20, 1997 and is headquartered in Beijing, China.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shineco, Inc. is a holding company, which through its subsidiaries, engages in the production and distribution of plant-based products. It operates through the following segments: Rapid Diagnostic and Other, Other Agricultural, and Healthy Meals Products. The Rapid Diagnostic and Other Products segment is conducted through Biowin, which specializes in the development, production and distribution of innovative rapid diagnostic products and related medical devices for the most common diseases. The Other Agricultural Products segment is conducted through Wintus, which specializes in producing, processing and distribution of agricultural products, such as silk and silk fabrics as well as trading of fresh fruit. The Healthy Meals Products segment is conducted through Fuzhou Meida, which specializes in developing healthy meals for people with slow metabolic health and those in recovery from metabolic disorders. The company was founded on August 20, 1997 and is headquartered in Beijing, China.

BEIJING, March 11, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that on March 4, 2022, the Company has signed a strategic cooperation framework agreement (the “Agreement”) on Shineco's Weifang Life Science Industrial Park Project (the “Project”) with the Development Service Center of Weifang Binhai Science and Technology Innovation Park in Shandong Province to build one of China's first city-level tumor classification diagnosis and treatment centers and an online telemedicine service platform, which would constitute Shineco's tumor diagnosis and treatment platform. The Company expects to complete the construction of its first city-level tumor classification diagnosis and treatment center (the “Shineco Diagnosis and Treatment Center” or “Center”) by the end of 2022. Through leverage respective advantages and resources, both parties expect to jointly build the Center and promote the implementation of digital medical care, internet hospitals, and the research and development of innovative medicine and devices.

Shineco, Inc. to Build Its First Tumor Classification Diagnosis and Treatment Center in Weifang City, Shandong Province

BEIJING, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company entered into a strategic cooperation agreement (the “Agreement”) with Beijing Xihuan Psychological Consulting Co., Ltd. (“XHPC”), a Beijing-based comprehensive psychological consulting company, on February 21, 2022 to jointly build an industry-university-research-medical collaborative platform (the “Platform”) for psychological rehabilitation of tumor patients. Shineco and XHPC plan to use the Platform to conduct research on critical topics, introduce the results of relevant research into the Company's tumor clinical treatment system, and improve the development of Shineco's digital tumor diagnosis and treatment.

Shineco, Inc. to Create an Industry-University-Research-Medical Collaborative Platform for Psychological Rehabilitation of Tumor Patients

BEIJING, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that on February 16, 2022, the Company entered into a strategic cooperation framework agreement (the “Agreement”) with Beijing Jinshengyun Pharmaceutical Technology Co., Ltd. (“JSY”), a Beijing-based outsourcing service company engaged in comprehensive drug and medical device development, for in-depth cooperation in the research and development (“R&D”) of innovative drugs and medical devices. Both parties plan to promote innovative drugs and medical devices and support the establishment of Shineco pharmaceutical R&D and innovation center.

Shineco, Inc. Announces Strategic Alliance to Enhance the Research and Development of Innovative Drugs and Medical Devices

BEIJING, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company has appointed Professor Qiyin Sun as the Chief Medical Consultant. Professor Sun will lead the research and innovation of the Company's tumor treatment and provide technical consultation in early tumor screening and tumor radiotherapy to support the commercialization of digital tumor diagnosis and treatment.

Shineco, Inc. Appoints Professor Qiyin Sun as Chief Medical Consultant

BEIJING, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that it has entered into a securities purchase agreement (the “Agreement”) for the sale of Gross Proceeds US$2.0 million of its registered common stock at a price of $6.8546 per share with GHS Investments, LLC (“GHS”), a leading private investment and management group providing financial solutions for high potential small cap enterprises.

Shineco, Inc. Announces Entering Into a Securities Purchase Agreement with GHS Investments, LLC with Gross Proceeds of $2.0 Million USD

As a Preemptive Action to Develop Comprehensive Medical and Healthcare Services

Shineco, Inc. Intends to Acquire a Controlling Interest of Xiang Peng You Kang (Beijing) Technology Co., Ltd., a Healthcare Services Company

BEIJING, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that it entered into a Memorandum of Understanding ("MOU") with Dr. Angus Hui, the founder and sole shareholder of Dragon Pride Limited (“Dragon Pride”), a renowned medical aesthetic service provider in Hong Kong, pursuant to which the Company has an exclusive right during a period of 90 days to negotiate the terms of an definitive agreement to acquire either 100% of the equity interest of Dragon Pride or not less than 50% of the equity interest of the Medical Aesthetic Center, subject to a definitive agreement.

Shineco, Inc. Explores Medical Aesthetic Industry by Entering into MOU with Dragon Pride Limited

News for Shineco Stock (SISI)